Adding Durvalumab to Chemoradiotherapy Does Not Improve Outcomes in Stage III NSCLC
Adding durvalumab to first-line chemoradiotherapy did not improve outcomes in patients with stage III NSCLC in the PACIFIC-2 trial.
Adding durvalumab to first-line chemoradiotherapy did not improve outcomes in patients with stage III NSCLC in the PACIFIC-2 trial.
Treatment with SNB-101 previously demonstrated tolerability among patients with solid tumors in a phase 1 trial.
The purpose of this European Society for Radiotherapy and Oncology (ESTRO) project, endorsed by the European Association of Urology, is to explore expert opinion on…
The requirement of large-scale expensive cancer screening trials spanning decades creates considerable barriers to the development, commercialisation, and implementation of novel screening tests. One way…
The addition of [177Lu]Lu-PSMA-617 to enzalutamide improved PSA progression-free survival providing evidence of enhanced anticancer activity in patients with metastatic castration-resistant prostate cancer with risk…
Foods that Fight Cancer – research shows that a diet filled with a variety of vegetables, fruits, whole grains, beans and other plant foods helps…
When Thelma Pollard was diagnosed with an aggressive soft tissue cancer called undifferentiated pleiomorphic sarcoma at age 74, local surgeons recommended hospice care. Instead, she…
For National Women’s Health Week, make sure you’re taking these preventive measures
Patients with CLL/SLL who received second-line venetoclax experienced monthly cost savings compared with those who received a second-line BTK inhibitor.
Circulating tumor DNA (ctDNA) holds promise as a biomarker for predicting clinical responses to therapy in solid tumors, and multiple ctDNA assays are in development.…
Lillian L. Siu discovered her passion while perusing employment ads in the Journal of Clinical Oncology. “I literally opened JCO, the Journal of Clinical Oncology,…